Has Iradj Sharim received payments from drug or device companies?

Yes. Drug and device makers reported $4,843 in general payments to Iradj Sharim across 138 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Iradj Sharim did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Iradj Sharim come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Iradj Sharim

Internal Medicine · Trenton, NJNPI 1790739423

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 138 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations.

$4,843in general payments, 2019–2025

Across 138 payments — averaging $35.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$839
AstraZeneca$586
Amgen$532
GSK$373
Novo Nordisk$330
Lilly USA, LLC$267
plus $2K from 16 others

What the payments were for

Food & beverage$4,843100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	18	$839
AstraZeneca	10	$586
Amgen	9	$532
GSK	14	$373
Novo Nordisk	23	$330
Lilly USA, LLC	9	$267
Amarin Pharma, Inc.	3	$261
Pfizer	7	$257
Sanofi-aventis U.S. LLC	9	$227
Novartis	8	$208
Avanir Pharmaceuticals, Inc.	6	$189
Boehringer Ingelheim	5	$154
Genentech USA, Inc.	2	$130
Valeritas, Inc.	1	$125
E.r. Squibb & Sons, L.L.C.	1	$89
Teva Pharmaceuticals USA, Inc.	2	$85
Kowa Pharmaceuticals America, Inc.	5	$71
Si-bone, Inc.	1	$66
Takeda Pharmaceuticals U.S.A., Inc.	2	$15
Medtronic	1	$14
Merck	1	$13
Daiichi Sankyo Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,843 in reported general payments places this provider in the 85th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey →

Other internal medicine in Trenton

Edward LaubTrenton$39K
David ShulkinMorristown$1.7M
Howard UdermanLakewood$955K
Darshi SunderamEast Orange$530K
Annika DrongeEmerson$401K
Stephen MarcellaNew Brunswick$331K
Viju VijaysadanKinnelon$325K
Mark MonaneWoodcliff Lake$268K
Martin BedigianLivingston$240K
Rameck HuntPlainsboro$217K

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →